A new study shows that a common oral bacterium linked to a virulent form of colorectal cancer could be driving tumor growth.
Significance of Findings
Fusobacterium nucleatum is of particular interest because the patients in which it’s detected have a poorer prognosis and survival rate, Susan Bullman, Fred Hutch cancer microbiome researcher and co-corresponding study author, explained in a news release.“Now we’re finding that a specific subtype of this microbe is responsible for tumor growth,” she said. “It suggests therapeutics and screening that target this subgroup within the microbiota would help people who are at a higher risk for more aggressive colorectal cancer.”
The specific subtype of the Fusobacterium—described as Fna C2—was found in half the tumors in the study. It was also found in higher quantities of stool samples of 627 colorectal patients compared to 619 healthy people in a separate analysis included in the study.
Fna C2 was one of two distinct lineages of Fusobacterium nucleatum noted in the colorectal tumors with 195 genetic differences from the other clade, or group of organisms with similar genetic traits, called Fna C1. Traits of Fna C2 indicate it could pass through stomach acid and then grow in the colon.
Hope for Prevention, Screening, and Treatment
“We have pinpointed the exact bacterial lineage that is associated with colorectal cancer, and that knowledge is critical for developing effective preventive and treatment methods,” co-corresponding author Christopher D. Johnston, Fred Hutch molecular microbiologist, said in the news release.Still, it could be some time before those tools are developed, mostly because more research is needed, Dr. Marty Makary, a cancer surgeon at Johns Hopkins told The Epoch Times.
Gut Disruption
The gut microbiota is a collection of trillions of bacteria, viruses, fungi, and other microorganisms. Until the last several decades, attention has honed in on pathogenic microbes and antibiotics that often wipe out the whole community. Newer studies are finding a relationship between the composition of the overall microbiome and many diseases.“We don’t know what we’re doing to the microbiome,” said Dr. Makary, a bestselling author whose latest book is “Blind Spots: When Medicine Gets It Wrong, and What It Means for Our Health.” “It may be antibiotics and other things we do may enable more inflammatory bacteria, and inflammation has been suggested to be a contributing factor to cancer.
The Role of Antibiotics
In fact, it could be modern medicine’s interventions that have caused the disruption in the first place. Dr. Makary noted research showing a relationship between antibiotic use—which can wipe out protective microbes in the gut microbiome—and colon polyps, a potential precursor to colon cancer.Lessons From History
While the new study makes it clear there’s an association between the microbiome and colorectal cancer, Dr. Makary said it’s possible there could be many microbes involved. Moving forward, he said it’s important that medical dogma be acknowledged and for open minds to prevail in studying the microbiome as a whole.“We’re seeing the tip of the iceberg when it comes to our understanding of the microbiome,” he said. “As long as we are only researching chemotherapy and not the exposures that cause cancer we’re never going to better understand the role of the microbiome in cancer and chronic disease.”
The possible microbial link with colon cancer raised in this study is not unlike the discovery that H. pylori can cause stomach ulcers, Dr. Makary noted.
Heliobacter pylori, a common bacteria that most people have, can sometimes damage stomach and small intestine tissues, causing a hyperinflammatory state that can lead to peptic ulcers in the upper digestive tract.
“The medical establishment laughed at the idea put forth by researchers and said, ‘We’re certain it’s stress, not one bacteria in the microbiome.’ but there was a direct relationship that was proven,” Dr. Makary said. “If we can acknowledge we have these blindspots that deserve research with the same methodological rigor that we apply to pharma research then we can start to have meaningful discoveries to get at the rising rates of cancer in young people.”